NEJM/X
Oct 1, 2025, 15:39
Boosting Stroke Thrombolysis․ Tirofiban Shows Promise in ASSET-IT Trial
The New England Journal of Medicine (NEJM), has shared a post on X:
“ASSET-IT phase 3 trial. Guidelines recommend intravenous thrombolysis within 4.5 hours after onset of acute ischemic stroke, but vascular reocclusion may occur.
Adjunct treatment with tirofiban might improve outcomes. Research findings are summarized in a new Quick Take video.”
Read more here.
Stay updated with Hemostasis Today.
-
Jan 8, 2026, 05:51Dominika Jędrzejewska Akbaş Links Sleep Deprivation, Obesity, and Stroke
-
Jan 8, 2026, 05:42Rob Maloney: A Bruise that Did Not Go Away…
-
Jan 8, 2026, 05:33Matías J Alet on Treating Early Neurological Deterioration in Lacunar Stroke
-
Jan 8, 2026, 05:11Thomas Meinel Shares The English Stroke Guidelines 2026
-
Jan 8, 2026, 05:03Hilla Ben-Pazi: We Were Pleased to Receive a Grant from the Israeli Ministry of Economy
-
Jan 8, 2026, 04:24Nikhil Agrawal Breaks Down Perioperative Anticoagulation
-
Jan 8, 2026, 03:58Louise St Germain Bannon Appointed Interim Executive Director of ISTH
-
Jan 8, 2026, 03:47Wolfgang Miesbach on Fernando Corrales-Medina’s Team’s Latest Cross-Sectional Study on Haemophilia
-
Jan 8, 2026, 03:28Rick Matthews: Powerful Perspective from Erin and the NBCA Team